Retatrutide Phase 3 Results: What the 2026 TRIUMPH Data Show

Retatrutide entered 2026 with unusually high expectations after earlier studies of its combined GIP, GLP-1 and glucagon receptor activity. The important change this year is that the evidence base moved into pivotal Phase 3 trials. That makes it possible to discuss retatrutide with more precision than simply repeating Phase 2 headlines.

TRIUMPH-1 moved the evidence into Phase 3

TRIUMPH-1 was a randomized, double-blind Phase 3 trial in adults with obesity or overweight without type 2 diabetes. The study was completed in 2026 and the primary results were published in the New England Journal of Medicine in September. Lilly reported an average body-weight reduction of 28.3% at 80 weeks in the highest studied group, while the trial also evaluated safety and obesity-related outcomes. These are trial results in a defined population, not a guarantee of an individual outcome.

TRIUMPH-2 and TRIUMPH-3 broadened the populations studied

Lilly also announced positive Phase 3 results from TRIUMPH-2, which enrolled adults with obesity or overweight and type 2 diabetes, and TRIUMPH-3, which studied adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes. The company reported average weight reductions of up to 20.8% in TRIUMPH-2 and 22.6% in TRIUMPH-3 at 80 weeks. Detailed peer-reviewed interpretation is particularly important because populations, endpoints and baseline risk differ between trials.

Why percentages alone are not the whole story

A headline percentage cannot describe an entire clinical trial. Researchers also examine discontinuations, adverse events, changes in metabolic markers, the proportion of participants reaching prespecified thresholds and whether effects are consistent across subgroups. Trial duration matters as well: an 80-week result answers a different question from a short proof-of-concept study.

Safety remains part of the Phase 3 question

Retatrutide acts on three hormone receptors, so the clinical programme evaluates both efficacy and tolerability. Gastrointestinal adverse events have been among the most commonly reported events in the development programme. The relevant safety picture comes from the complete trial datasets and regulatory review, not from weight-loss numbers alone.

Retatrutide is still investigational

Despite the positive Phase 3 programme, retatrutide is not currently an approved medicine. Lilly states that it remains investigational and has outlined plans for regulatory submissions. Approval, indications, labelling and availability depend on review by regulators and cannot be assumed from successful trials.